Tatsuya Okuzumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tatsuya Okuzumi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Akira Nakayama
Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan
1 shared publication- Brian A. Mendelsohn
Discovery Biotherapeutics, Exelixis, Inc., Alameda, California
1 shared publication Eiji Nakanishi
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc. 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, 210-8681 Japan
1 shared publication- Kazutoshi Takahashi
Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc., Kawasaki-shi, Japan
1 shared publication - Kei Yamada
Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA
1 shared publication Sayaka Kawaguchi
Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan
1 shared publication
Latest Publications
- Open Access
- 27 September 2021
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 18 (11) , 4058-4066
Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody–Drug Conjugates
To overcome a lack of selectivity during the chemical modification of native non-engineered antibodies, we have developed a technology platform termed “AJICAP” for the site-specific chemical conjugation of antibodies through the use of a class of IgG Fc-affinity reagents. To date, a limited number of antibody–drug conjugates (ADCs) have been synthesized via this approach, and no toxicological study was reported. Herein, we describe the compatibility and robustness of AJICAP technology, which enabled the synthesis of a wide variety of ADCs. A stability assessment of a thiol-modified antibody synthesized by AJICAP technology indicated no appreciable increase in aggregation or decomposition upon prolonged storage, indicating that the unexpectedly stable thiol intermediate has a great potential intermediate for payload or linker screening or large-scale manufacturing. Payload conjugation with this stable thiol intermediate generated several AJICAP-ADCs. In vivo xenograft studies indicated that the AJICAP-ADCs displayed significant tumor inhibition comparable to benchmark ADC Kadcyla. Furthermore, a rat pharmacokinetic analysis and toxicology study indicated an increase in the maximum tolerated dose, demonstrating an expansion of the AJICAP-ADC therapeutic index, compared with stochastic conjugation technology. This is the first report of the therapeutic index estimation of site-specific ADCs produced by utilizing Fc affinity reagent conjugation. The described site-specific conjugation technology is a powerful platform to enable next-generation ADCs through reduced heterogeneity and enhanced therapeutic index.
- 27 September 2021
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 18 (11) , 4058-4066
Open AccessChemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody–Drug Conjugates
To overcome a lack of selectivity during the chemical modification of native non-engineered antibodies, we have developed a technology platform termed “AJICAP” for the site-specific chemical conjugation of antibodies through the use of a class of IgG Fc-affinity reagents. To date, a limited number of antibody–drug conjugates (ADCs) have been synthesized via this approach, and no toxicological study was reported. Herein, we describe the compatibility and robustness of AJICAP technology, which enabled the synthesis of a wide variety of ADCs. A stability assessment of a thiol-modified antibody synthesized by AJICAP technology indicated no appreciable increase in aggregation or decomposition upon prolonged storage, indicating that the unexpectedly stable thiol intermediate has a great potential intermediate for payload or linker screening or large-scale manufacturing. Payload conjugation with this stable thiol intermediate generated several AJICAP-ADCs. In vivo xenograft studies indicated that the AJICAP-ADCs displayed significant tumor inhibition comparable to benchmark ADC Kadcyla. Furthermore, a rat pharmacokinetic analysis and toxicology study indicated an increase in the maximum tolerated dose, demonstrating an expansion of the AJICAP-ADC therapeutic index, compared with stochastic conjugation technology. This is the first report of the therapeutic index estimation of site-specific ADCs produced by utilizing Fc affinity reagent conjugation. The described site-specific conjugation technology is a powerful platform to enable next-generation ADCs through reduced heterogeneity and enhanced therapeutic index.
- 9 October 2003
- Published by American Chemical Society (ACS) in Journal of Combinatorial Chemistry
- Vol. 5 (6) , 756-759
Efficient Solid-Phase Synthesis of Diverse 2-Aminoquinazolin-4-ones from Resin-Bound Anilines
- 9 October 2003
- Published by American Chemical Society (ACS) in Journal of Combinatorial Chemistry
- Vol. 5 (6) , 756-759
Efficient Solid-Phase Synthesis of Diverse 2-Aminoquinazolin-4-ones from Resin-Bound Anilines